Immunological Mechanisms Underneath the Efficacy of Cancer Therapy

The hallmarks of cancer

Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219

Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516

The future of immune checkpoint therapy

Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878

Neoantigens in cancer immunotherapy

Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237

Immunogenic cell death and DAMPs in cancer therapy

Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223

Calreticulin exposure dictates the immunogenicity of cancer cell death

Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216

Immunogenic cell death in cancer and infectious disease

Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119

Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 2×

IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896

T cell exclusion, immune privilege, and the tumor microenvironment

Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,539

Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy

Kärre, K., Ljunggren, H., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,333

Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment

Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., et al. (2013) · Science · doi:10.1126/science.1240527 · Cited by 2,251

HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C

Braud, V. M., Allan, D., O'Callaghan, C. A., Söderström, K., D’Andrea, A., Ogg, G. S., Lazetic, S., Young, N. T., Bell, J. I., Phillips, J. H., et al. (1998) · Nature · doi:10.1038/35869 · Cited by 2,226

Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis

Chang, C.-H., Curtis, J. D., Maggi, L. B., Faubert, B., Villarino, A. V., O’Sullivan, D., Huang, S. C.-C., van der Windt, G. J. W., Blagih, J., Qiu, J., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.016 · Cited by 2,204

The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide

Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050

Towards a systems understanding of MHC class I and MHC class II antigen presentation

Neefjes, J., Jongsma, M. L. M., Paul, P., & Bakke, O. (2011) · Nature Reviews Immunology · doi:10.1038/nri3084 · Cited by 2,044

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022

A History of Cancer Chemotherapy

DeVita, V. T., & Chu, E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6611 · Cited by 1,973

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors

Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898

Immunological effects of conventional chemotherapy and targeted anticancer agents

Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512

Adaptive immunity maintains occult cancer in an equilibrium state

Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,438

Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice

Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

Ghiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, É., Cesne, A. L., Zitvogel, L., & Chauffert, B. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0225-8 · Cited by 1,285

5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity

Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245

Immunogenic death of colon cancer cells treated with oxaliplatin

Tesnière, A., Schlemmer, F., Boige, V., Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apétoh, L., Barault, L., et al. (2009) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,224

Autophagy in malignant transformation and cancer progression

Galluzzi, L., Pietrocola, F., Bravo‐San Pedro, J. M., Amaravadi, R. K., Baehrecke, E. H., Cecconi, F., Codogno, P., Debnath, J., Gewirtz, D. A., Karantza, V., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201490784 · Cited by 1,182

History of myeloid-derived suppressor cells

Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148

Cellular Oncogenes and Multistep Carcinogenesis

Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Science · doi:10.1126/science.6356358 · Cited by 1,111

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

Huang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0883 · Cited by 1,054

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability

Mlecnik, B., Bindea, G., Angell, H. K., Maby, P., Angelova, M., Tougeron, D., Church, S. E., Lafontaine, L., Fischer, M., Fredriksen, T., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.025 · Cited by 1,034

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

Denkert, C., von Minckwitz, G., Brase, J. C., Sinn, B. V., Gade, S., Kronenwett, R., Pfitzner, B. M., Salat, C., Loi, S., Schmitt, W., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1967 · Cited by 1,033

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

Pfirschke, C., Engblom, C., Rickelt, S., Cortez‐Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.11.024 · Cited by 971

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

Ghiringhelli, F., Larmonier, N., Schmitt, E., Parcellier, A., Cathelin, D., Garrido, C., Chauffert, B., Solary, É., Bonnotte, B., & Martin, F. (2004) · European Journal of Immunology · doi:10.1002/eji.200324181 · Cited by 878

Regulation of Ligands for the NKG2D Activating Receptor

Raulet, D. H., Gasser, S., Gowen, B. G., Deng, W., & Jung, H. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095951 · Cited by 877

Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death

Panaretakis, T., Kepp, O., Brockmeier, U., Tesniere, A., Bjorklund, A., Chapman, D. C., Durchschlag, M., Joza, N., Pierron, G., van Endert, P., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.1 · Cited by 848

Metabolic targets for cancer therapy

Galluzzi, L., Kepp, O., Heiden, M. G. V., & Kroemer, G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4145 · Cited by 731

Dendritic Cells in Tumor-Associated Tertiary Lymphoid Structures Signal a Th1 Cytotoxic Immune Contexture and License the Positive Prognostic Value of Infiltrating CD8+ T Cells

Goc, J., Germain, C., Vo-Bourgais, T. K. D., Mansuet‐Lupo, A., Klein, C., Knockaert, S., de Chaisemartin, L., Ouakrim, H., Becht, É., Alifano, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1342 · Cited by 713

VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer

Terme, M., Pernot, S., Marcheteau, E., Sandoval, F., Benhamouda, N., Colussi, O., Dubreuil, O., Carpentier, A. F., Tartour, E., & Taieb, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2325 · Cited by 684

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

Kim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676

Metronomic chemotherapy: new rationale for new directions

Pasquier, E., Kavallaris, M., & André, N. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.82 · Cited by 666

Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death

Golden, E. B., Frances, D., Pellicciotta, I., Demaria, S., Barcellos‐Hoff, M. H., & Formenti, S. C. (2014) · OncoImmunology · doi:10.4161/onci.28518 · Cited by 651

Conditioning regimens for hematopoietic cell transplantation: one size does not fit all

Gyurkocza, B., & Sandmaier, B. M. (2014) · Blood · doi:10.1182/blood-2014-02-514778 · Cited by 616

Natural killer cell memory in infection, inflammation and cancer

Cerwenka, A., & Lanier, L. L. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2015.9 · Cited by 593

From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer

Angell, H., & Galon, J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.03.004 · Cited by 574

Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4

Probst, H. C., McCoy, K. D., Okazaki, T., Honjo, T., & van den Broek, M. F. (2005) · Nature Immunology · doi:10.1038/ni1165 · Cited by 568

Radiation-Induced IFN-γ Production within the Tumor Microenvironment Influences Antitumor Immunity

Lugade, A. A., Sorensen, E. W., Gerber, S. A., Moran, J. P., Frelinger, J. G., & Lord, E. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.3132 · Cited by 485

Reversing T-cell Dysfunction and Exhaustion in Cancer

Zarour, H. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1849 · Cited by 462

Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1

Vacchelli, E., Ma, Y., Baracco, E. E., Sistigu, A., Enot, D. P., Pietrocola, F., Yang, H., Adjemian, S., Chaba, K., Semeraro, M., et al. (2015) · Science · doi:10.1126/science.aad0779 · Cited by 452 · cited 2×

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

Liu, L., Mayes, P. A., Eastman, S., Shi, H., Yadavilli, S., Zhang, T., Yang, J., Seestaller-Wehr, L., Zhang, S.-Y., Hopson, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2339 · Cited by 446

Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers

Li, H., Chiappinelli, K. B., Guzzetta, A. A., Easwaran, H., Yen, R.-W. C., Vatapalli, R. J., Topper, M. J., Luo, J., Connolly, R. M., Azad, N. S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1782 · Cited by 428

Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?

Löb, S., Königsrainer, A., Rammensee, H., Opelz, G., & Terness, P. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2639 · Cited by 421

Combinatorial Strategies for the Induction of Immunogenic Cell Death

Bezu, L., Gomes-da-Silva, L. C., Dewitte, H., Breckpot, K., Fucikova, J. P., Špíšek, R., Galluzzi, L., Kepp, O., & Kroemer, G. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00187 · Cited by 400

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses

Liu, W. M., Fowler, D. W., Smith, P., & Dalgleish, A. G. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605465 · Cited by 362

Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer

Brambilla, E. M., Teuff, G. L., Marguet, S., Lantuéjoul, S., Dunant, A., Graziano, S. L., Pirker, R., Douillard, J.-Y., Chevalier, T. L., Filipits, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0970 · Cited by 351

Radiation as an immunological adjuvant: current evidence on dose and fractionation

Demaria, S., & Formenti, S. C. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00153 · Cited by 346

Natural and therapy-induced immunosurveillance in breast cancer

Kroemer, G., Senovilla, L., Galluzzi, L., André, F., & Zitvogel, L. (2015) · Nature Medicine · doi:10.1038/nm.3944 · Cited by 316

Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors

Rusakiewicz, S., Semeraro, M., Sarabi, M., Desbois, M., Locher, C., Mendez, R., Vimond, N., Concha, Á., Garrido, F., Isambert, N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0371 · Cited by 305

Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy.

Demaria, S., Volm, M., Shapiro, R. L., Yee, H. T., Oratz, R., Formenti, S. C., Muggia, F. M., & Symmans, W. F. (2001) · PubMed · Cited by 303

Chemotherapeutics and Radiation Stimulate MHC Class I Expression through Elevated Interferon-beta Signaling in Breast Cancer Cells

Wan, S., Pestka, S., Jubin, R. G., Lyu, Y. L., Tsai, Y.-C., & Liu, L. F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032542 · Cited by 295

The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death

Pozzi, C., Cuomo, A., Spadoni, I., Magni, E., Silvola, A., Conte, A., Sigismund, S., Ravenda, P. S., Bonaldi, T., Zampino, M. G., et al. (2016) · Nature Medicine · doi:10.1038/nm.4078 · Cited by 292

Antitumor Effect of Paclitaxel Is Mediated by Inhibition of Myeloid-Derived Suppressor Cells and Chronic Inflammation in the Spontaneous Melanoma Model

Sevko, A., Michels, T., Vrohlings, M., Umansky, L., Beckhove, P., Kato, M., Shurin, G. V., Shurin, M. R., & Umansky, V. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202781 · Cited by 254

Mutational Landscape and Sensitivity to Immune Checkpoint Blockers

Chabanon, R. M., Pedrero, M., Lefèbvre, C., Marabelle, A., Soria, J., & Postel-Vinay, S. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0903 · Cited by 236

Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors

Epling‐Burnette, P. K., Bai, F., Painter, J. S., Rollison, D. E. M., Salih, H. R., Krusch, M., Zou, J., Ku, E., Zhong, B., Boulware, D. C., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035519 · Cited by 232

Metabolic crosstalk between host and pathogen: sensing, adapting and competing

Olive, A. J., & Sassetti, C. M. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.12 · Cited by 231

The biology and management of systemic anaplastic large cell lymphoma

Hapgood, G., & Savage, K. J. J. (2015) · Blood · doi:10.1182/blood-2014-10-567461 · Cited by 207

Natural Killer Cell IFN-γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor–Bearing Patients

Ménard, C., Blay, J.-Y., Borg, C., Michiels, S., Ghiringhelli, F., Robert, C., Nonn, C., Chaput, N., Taïeb, J., Delahaye, N. F., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3807 · Cited by 202

Ligands for natural killer cell–activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias

Nowbakht, P., Ionescu, M.-C. S., Rohner, A., Kalberer, C. P., Rossy, E., Mori, L., Cosman, D. J., Libero, G. D., & Wodnar‐Filipowicz, A. (2005) · Blood · doi:10.1182/blood-2004-07-2585 · Cited by 194

Myeloid-Derived Suppressor Cell Inhibition of the IFN Response in Tumor-Bearing Mice

Mundy-Bosse, B. L., Lesinski, G. B., Jaime‐Ramirez, A. C., Benninger, K. L., Khan, M., Kuppusamy, P., Guenterberg, K. D., Kondadasula, S. V., Chaudhury, A. R., Perle, K. M. D. L., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2670 · Cited by 189

RAE1 Ligands for the NKG2D Receptor Are Regulated by STING-Dependent DNA Sensor Pathways in Lymphoma

Lam, A. R., Bert, N. L., Ho, S. S. W., Shen, Y. J., Tang, M. L. F., Xiong, G. M., Croxford, J. L., Koo, C. X., Ishii, K. J., Akira, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1703 · Cited by 179

Cisplatin Resistance Associated with PARP Hyperactivation

Michels, J., Vitale, I., Galluzzi, L., Adam, J., Olaussen, K. A., Kepp, O., Senovilla, L., Talhaoui, I., Guegan, J., Enot, D. P., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3000 · Cited by 176

Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice

Pfannenstiel, L. W., Lam, S. S. K., Emens, L. A., Jaffee, E. M., & Armstrong, T. D. (2010) · Cellular Immunology · doi:10.1016/j.cellimm.2010.03.001 · Cited by 166

Adverse Immunoregulatory Effects of 5FU and CPT11 Chemotherapy on Myeloid-Derived Suppressor Cells and Colorectal Cancer Outcomes

Kanterman, J., Sade-Feldman, M., Biton, M., Ish‐Shalom, E., Lasry, A., Goldshtein, A., Hubert, A., & Baniyash, M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0657 · Cited by 166

Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer

Fucikova, J., Moserova, I., Urbanova, L., Bezu, L., Kepp, O., Cremer, I., Salek, C., Strnad, P., Kroemer, G., Galluzzi, L., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00402 · Cited by 159

Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer

Li, J.-Y., Duan, X.-F., Wang, L.-P., Xu, Y.-J., Huang, L., Zhang, T.-F., Liu, J.-Y., Li, F., Zhang, Z., Yue, D.-L., et al. (2014) · Journal of Immunology Research · doi:10.1155/2014/286170 · Cited by 157

MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro

Angell, T. E., Lechner, M. G., Jang, J. K., LoPresti, J. S., & Epstein, A. L. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0879 · Cited by 153

Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients

Desar, I. M. E., Jacobs, J. F. M., Hulsbergen‐vandeKaa, C. A., Oyen, W. J. G., Mulders, P., van der Graaf, W. T. A., Adema, G. J., van Herpen, C. M. L., & de Vries, I. J. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25674 · Cited by 140

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

Buqué, A., Bloy, N., Aranda, F., Castoldi, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Marabelle, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008814 · Cited by 132

Downregulation of MHC-I Expression Is Prevalent but Reversible in Merkel Cell Carcinoma

Paulson, K. G., Tegeder, A. R., Willmes, C., Iyer, J. G., Afanasiev, O. K., Schrama, D., Koba, S., Thibodeau, R. M., Nagase, K., Simonson, W. T., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0005 · Cited by 132

Lung cancer is associated with decreased expression of perforin, granzyme B and interferon (IFN)-γ by infiltrating lung tissue T cells, natural killer (NK) T-like and NK cells

Hodge, G. L., Barnawi, J., Jurisevic, C. A., Moffat, D., Holmes, M., Reynolds, P. N., Jersmann, H. P. A., & Hodge, S. J. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12392 · Cited by 127

Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ

Ho, P.-C., Meeth, K. M., Tsui, Y.-C., Srivastava, B., Bosenberg, M. W., & Kaech, S. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3461 · Cited by 126

The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer

Ladoire, S., Enot, D., Senovilla, L., Ghiringhelli, F., Poirier-Colame, V., Chaba, K., Semeraro, M., Chaix, M., Penault-Llorca, F., Arnould, L., et al. (2016) · Autophagy · doi:10.1080/15548627.2016.1154244 · Cited by 117

Lapatinib and doxorubicin enhance the S tat1‐dependent antitumor immune response

Hannesdóttir, L., Tymoszuk, P., Parajuli, N., Wasmer, M.-H., Philipp, S., Daschil, N., Datta, S., Koller, J., Tripp, C. H., Stoitzner, P., et al. (2013) · European Journal of Immunology · doi:10.1002/eji.201242505 · Cited by 113

Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice

González-Aparicio, M., Alzuguren, P., Mauleón, I., Medina‐Echeverz, J., Hervás‐Stubbs, S., Mancheño, U., Berraondo, P., Crettaz, J. S., González‐Aseguinolaza, G., Prìeto, J., et al. (2010) · Gut · doi:10.1136/gut.2010.211722 · Cited by 112

Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8 + T-cell responses and immune memory

Wu, J., & Waxman, D. J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1005521 · Cited by 102

The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible “hard” lesions

Garrido, F., Algarra, I., & Garcia-Lora, A. M. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0893-2 · Cited by 102

Development of Minimal Residual Disease–Directed Therapy in Acute Myeloid Leukemia

Freeman, S. D., Jovanovic, J. V., & Grimwade, D. J. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.009 · Cited by 90

Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways

Sawant, A., Schafer, C. C., Jin, T. H., Zmijewski, J. W., Tse, H. M., Roth, J. C., Sun, Z., Siegal, G. P., Thannickal, V. J., Grant, S. C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0987 · Cited by 88

Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer

Colangelo, T., Polcaro, G., Ziccardi, P., Pucci, B., Muccillo, L., Galgani, M., Fucci, A., Milone, M. R., Budillon, A., Santopaolo, M., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.28 · Cited by 88

Tumor‐infiltrating dendritic cells exhibit defective cross‐presentation of tumor antigens, but is reversed by chemotherapy

McDonnell, A. M., Lesterhuis, W. J., Khong, A., Nowak, A. K., Lake, R., Currie, A. J., & Robinson, B. W. S. (2014) · European Journal of Immunology · doi:10.1002/eji.201444722 · Cited by 87

Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer

Homma, Y., Taniguchi, K., Nakazawa, M., Matsuyama, R., Mori, R., TAKEDA, K., Ichikawa, Y., Tanaka, K., & Endo, I. (2013) · Clinical & Translational Oncology · doi:10.1007/s12094-013-1079-0 · Cited by 83

Considerations for the successful co-development of targeted cancer therapies and companion diagnostics

Fridlyand, J., Simon, R. M., Walrath, J. C., Roach, N., Buller, R. E., Schenkein, D. P., Flaherty, K. T., Allen, J. D., Sigal, E. V., & Scher, H. I. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4101 · Cited by 82

Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation

He, S., Yin, T., Li, D., Gao, X., Wan, Y., Ma, X., Ye, T., Guo, F., Sun, J., Lin, Z., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-186 · Cited by 76

Effect of Pemetrexed on Innate Immune Killer Cells and Adaptive Immune T Cells in Subjects With Adenocarcinoma of the Pancreas

Davis, M., Conlon, K. C., Bohac, G. C., Barcenas, J., Leslie, W., Watkins, L., Lamzabi, I., Deng, Y., Li, Y., & PLATE, J. M. D. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31826c8a4f · Cited by 75

Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: Role of uric acid accumulation in gemcitabine-induced MICA/B expression

Xu, X., Rao, G., Groh, V., Spies, T. A., Gattuso, P., Kaufman, H. L., PLATE, J. M. D., & Prinz, R. A. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-194 · Cited by 71

EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells

Kim, H., Kim, S.-H., Kim, M.-J., Kim, S.-J., Park, S.-J., Chung, J.-S., Bae, J.-H., & Kang, C.-D. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31821b724a · Cited by 63

Decreased NKG2D expression on NK cells correlates with impaired NK cell function in patients with gastric cancer

Saito, H., Osaki, T., & Ikeguchi, M. (2011) · Gastric Cancer · doi:10.1007/s10120-011-0059-8 · Cited by 62

Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Patients Undergoing Adjuvant Chemotherapy

Vacchelli, E., Enot, D. P., Pietrocola, F., Zitvogel, L., & Kroemer, G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0294 · Cited by 61

5-Fluorouracil and Interferon-α Immunochemotherapy Enhances Immunogenicity of Murine Pancreatic Cancer Through Upregulation of NKG2D Ligands and MHC Class I

Khallouf, H., Märten, A., Serba, S., Teichgräber, V., Büchler, M. W., Jäger, D., & Schmidt, J. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31824b3a76 · Cited by 58

Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma

Lowe, D. B., Bose, A., Taylor, J. L., Tawbi, H. A.-H., Lin, Y., Kirkwood, J. M., & Storkus, W. J. (2014) · OncoImmunology · doi:10.4161/onci.27589 · Cited by 47

Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15Rα and NKG2D Triggering

Romero, A. I., Chaput, N., Poirier-Colame, V., Rusakiewicz, S., Jacquelot, N., Chaba, K., Mortier, E., Jacques, Y., Caillat‐Zucman, S., Flament, C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1186 · Cited by 43

Serial Low Doses of Sorafenib Enhance Therapeutic Efficacy of Adoptive T Cell Therapy in a Murine Model by Improving Tumor Microenvironment

Chuang, H., Chang, Y.-F., Liu, R.-S., & Hwang, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109992 · Cited by 38

Immunology of a Transmissible Cancer Spreading among Tasmanian Devils

Woods, G. M., Howson, L. J., Brown, G. K., Tovar, C., Kreiss, A., Corcoran, L. M., & Lyons, A. B. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500131 · Cited by 29

Abstract 5101: Biomarker identification in non-small cell lung cancer (NSCLC) with activity-based proteomics

Wiedl, T., Arni, S., Roschitzki, B., Grossmann, J., Soltermann, A., Hillinger, S., Aebersold, R. H., & Weder, W. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-5101 · Cited by 19

Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor

Kivlin, C. M., Watson, K. L., Sannaa, G. A. A., Belousov, R., Ingram, D. R., Huang, K.-L., May, C. D., Bolshakov, S. V., Landers, S. M., Kalam, A. A., et al. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1108486 · Cited by 16

Long‐term molecular remission with persistence of BCR ‐ ABL 1‐specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia‐positive ALL

Riva, G., Luppi, M., Lagreca, I., Barozzi, P., Quadrelli, C., Vallerini, D., Zanetti, E., Basso, S., Forghieri, F., Morselli, M., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12612 · Cited by 8

Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018.

Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680

Mitochondrial control of inflammation

Marchi, S., Guilbaud, E., Tait, S. W. G., Yamazaki, T., & Galluzzi, L. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00760-x · Cited by 1,027

Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics

Garg, A. D., More, S., Rufo, N., Meçe, O., Sassano, M. L., Agostinis, P., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1386829 · Cited by 288

Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology

Vanmeerbeek, I., Sprooten, J., Ruysscher, D. D., Tejpar, S., Vandenberghe, P., Fucikova, J. P., Špíšek, R., Zitvogel, L., Kroemer, G., Galluzzi, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1703449 · Cited by 231

Radiation-induced Cell Death and Its Mechanisms

Jiao, Y., Cao, F., & Liu, H. (2022) · Health Physics · doi:10.1097/hp.0000000000001601 · Cited by 239

Immune Effects of Conventional Cancer Therapeutics

Demaria, S., & Galluzzi, L. (2018) · Springer Publishing Company eBooks · doi:10.1891/9781617052736.0022

Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy

Proietti, E., Moschella, F., Capone, I., & Belardelli, F. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.11.005 · Cited by 50

Immunomodulation by targeted anticancer agents

Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212

Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer

Ramakrishnan, R., & Gabrilovich, D. I. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0930-1 · Cited by 74

Immunological effects of conventional chemotherapy and targeted anticancer agents

Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530